BLENREP is GSK’s fifth major medicine approval in 2020 across areas of significant unmet medical need such as cancer, HIV and chronic kidney disease.

GSK is currently planning to start a Phase 3 trial to explore the use of Blenrep as an earlier intervention for multiple myeloma. “The compelling overall survival data from the DREAMM-7 trial ...

Bristol Myers Squibb (BMY) and GSK PLC (GSK) are among the largest global biopharma companies with broad and diverse ...

FDA extends GSK’s Blenrep combo review; new PDUFA date set for October 23. Phase 3 trials show Blenrep combos significantly improve survival outcomes. See what Wall Street is buying with instant ...

(RTTNews) - GSK plc (GSK, GSK.L) issued an update on FDA advisory committee review of Blenrep combinations for patients with relapsed/refractory multiple myeloma. GSK said it remains confident in ...

GSK’s latest trial results reveal that Blenrep, in combination with other drugs, significantly reduces the risk of death in multiple myeloma patients by 42% compared to the standard treatment.

In 2022, GSK withdrew the U.S. marketing authorization for Blenrep following the FDA request, based on the previously announced outcome of the DREAMM-3 Phase 3 confirmatory trial, which did not ...

GSK shares fell after a Food and Drug Administration advisory committee voted against approval of the company's Blenrep drug, a setback for its bid to reintroduce the blood-cancer treatment in the ...

GlaxoSmithKline’s Blenrep combinations for treating relapsed multiple myeloma have been accepted for review by the US FDA, supported by promising results from the DREAMM-7 and DREAMM-8 trials.

In 2022, GSK withdrew the U.S. marketing authorization for Blenrep following the FDA request, based on the previously announced outcome of the DREAMM-3 Phase 3 confirmatory trial, which did not ...